ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

"In biotech securities cases, the core issue is often whether the company was accurately representing its data and trial design," said Reed Kathrein, the Hagens Berman partner leading the litigation. "The suit alleges that aTyr concealed material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy—while emphasizing a multi-billion- dollar market. We are scrutinizing whether these prior statements about the drug's prospects cr ...